Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
about
The role of fatty acid binding proteins in metabolic syndrome and atherosclerosisTreatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activitiesMechanisms by which diabetes increases cardiovascular disease.Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts.Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular diseaseChronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.Oxidized low-density lipoprotein suppresses expression of prostaglandin E receptor subtype EP3 in human THP-1 macrophagesSmall lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.Genetics, genomics and proteomics in atherosclerosis research.Serum adipocyte fatty acid-binding protein in the critically illAdipose tissue and the metabolic syndrome: focusing on adiponectin and several novel adipokines.Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages.Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?Effects of oxidized low- and high-density lipoproteins on gene expression of human macrophages.Lipid chaperones and metabolic inflammation.Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.Tamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathways.Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?Atorvastatin inhibits CD68 expression in aortic root through a GRP78-involved pathway.The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers.Molecular Dynamics Exploration of Selectivity of Dual Inhibitors 5M7, 65X, and 65Z toward Fatty Acid Binding Proteins 4 and 5
P2860
Q28271189-A374E260-2572-4D67-BFC5-BA04CCB8C496Q28305340-15D99007-E8EC-4CA3-9340-E8EF301EBEF8Q28513582-0ED6E643-4785-497E-9F05-CCF6E02DD756Q30441275-CCD0C2FD-F119-49C5-9F8D-423C6E851987Q31032707-C27428D3-17F4-44B2-87BD-0360B8077AE4Q33649348-7AAD47A6-75F9-48BE-AADE-8AD5BC6FAE83Q34565501-598B88FD-0C1F-4280-B968-401A8A5EAB34Q34672088-DEA7BC18-1E43-4DB8-9AC5-324A297DCD7EQ35042217-613C3F11-71AF-4A41-B79C-C2D2DE7D7E5CQ35355559-C82EF6E2-58AE-4C3B-802C-D6A7370EC601Q35859743-2E098F51-CFFB-4DBC-B779-97B11B1CEF52Q36265225-FC76DA43-3C1E-42AB-9CDD-ABEACC983FCDQ36902526-C0D8914D-8AE9-4806-831F-F372BBD88890Q37755109-14C4B7BD-1804-4176-9ADF-05959DA86A2BQ37989491-F7B69566-CD64-4214-B552-272276B7AB49Q38050907-DF5F50D8-9F75-4218-A48D-44D7DDF14218Q38309244-E9F7ECBB-88E0-4434-B023-72916F0AA097Q38908903-D3822095-5B07-43C2-A18C-4726DE59C966Q42488837-C833B89B-795B-4A82-B11A-A71BB856D392Q50874092-9749C629-48DB-4F3B-A74D-3F824567AB38Q51491919-5DC7BF8F-A533-44F1-8EE2-37D835F578B8Q51746469-20656A2C-3D2B-41DC-8BA6-BBBA37E812B1Q53189724-4AE6F976-40CB-47C2-A889-0EFB37FCD02EQ58710194-FA027CBE-01BB-4B6B-918D-08311BC34898
P2860
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
@en
type
label
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
@en
prefLabel
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
@en
P2093
P50
P1476
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
@en
P2093
Manuel Vázquez-Carrera
Rosa M Sánchez
Silvia Peñuelas
P304
P356
10.1016/J.BBRC.2004.04.021
P577
2004-05-01T00:00:00Z